In this episode of EyePod, Ora Clinical’s Keith Lane discusses uveitis and flare ups, as well as challenges in clinical trials.

Keith Lane of Orange Clinical joins us to discuss the current state of gene therapy and its standardized endpoints, and the challenges gene therapy has faced, particularly in relation to ophthalmology.

Retinopathy of prematurity expert C. Armitage Harper, III, MD, of the Austin Retina Associates in Austin, Texas, discusses his experience in treating ROP cases across the globe, and his mission prevent pre-term blindness in infants. 

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Michael Rivers, MD, director of Ophthalmology at Modernizing Medicine, discusses Aetna's new policy requiring prior authorization for cataract surgery, its impact on ophthalmologists and patients, as well as potential solutions — and additional issues — that may arise in the future as a result. 

Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.

Uday Devgan, MD, FACS, of Devgan Eye Surgery in Los Angeles and Beverly Hills, CA, answers a few key questions his patients have asked when considering cataract surgery.

Thomas Brunner, president & CEO, Glaucoma Research Foundation, San Francisco, CA, shares his thoughts on how living through a pandemic has influenced and altered his perspective on life — both personally and professionally — for the better. 

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, offers an update on optimization and surgical modifications of newer glaucoma surgeries in preop and postop settings.

Ophthalmology Times®' Sheryl Stevenson speaks with Marc Mathias, MD, a retinal specialist from Children’s Hospital Colorado, who offers insight on managing cases of inherited retinal dystrophies in pediatric patients, as well as an update on the rapidly changing treatment landscape, thanks to ongoing clinical trials in novel IRD and genetic therapies.